|
|
 Previous Article | Table of Contents | Next Article 
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
OW Press, F Appelbaum, JA Ledbetter, PJ Martin, J Zarling, P Kidd and ED Thomas
Four patients with refractory malignant B cell lymphomas were treated with
continuous intravenous (IV) infusions of murine monoclonal antibody (MoAb)
1F5 (anti-CD20) over five to ten days. Dose-dependent levels of free serum
1F5 were detected in all patients. Two patients had circulating tumor cells
and in both cases 90% of malignant cells were eliminated from the blood
stream within four hours of initiation of serotherapy. Antigenic modulation
did not occur, and sustained reduction of circulating tumor cells was
observed throughout the duration of the infusions. Serial bone marrow
aspirations and lymph node biopsies were examined by immunoperoxidase and
immunofluorescence techniques to ascertain MoAb penetration into
extravascular sites. High doses (100 to 800 mg/m2/d and high serum 1F5
levels (13 to 190 micrograms/mL) were required to coat tumor cells in these
compartments in contrast to the low doses that were adequate for depletion
of circulating cells. Clinical response appeared to correlate with dose of
MoAb administered with progressive disease (52 mg), stable disease (104
mg), minor response (1,032 mg), and partial response (2,380 mg) observed in
consecutive patients. The patient treated with the highest 1F5 dose
achieved a 90% reduction in evaluable lymph node disease, but the duration
of this remission was brief (six weeks). This study demonstrates that high
doses of 1F5 can be administered to patients with negligible toxicity by
continuous infusion and that clinical responses can be obtained in patients
given greater than 1 g of unmodified antibody over a ten-day period.
Volume 69,
Issue 2,
pp. 584-591,
02/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. A. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, and M. Dreyling
Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma
Oncologist,
October 1, 2009;
14(suppl_2):
4 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Green, J. M. Pagel, E. R. Nemecek, Y. Lin, A. Kenoyer, A. Pantelias, D. K. Hamlin, D. S. Wilbur, D. R. Fisher, J. G. Rajendran, et al.
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
Blood,
August 6, 2009;
114(6):
1226 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Hayden-Ledbetter, C. G. Cerveny, E. Espling, W. A. Brady, L. S. Grosmaire, P. Tan, R. Bader, S. Slater, C. A. Nilsson, D. S. Barone, et al.
CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
Clin. Cancer Res.,
April 15, 2009;
15(8):
2739 - 2746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Fisher, S. Shen, and R. F. Meredith
MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
J. Nucl. Med.,
April 1, 2009;
50(4):
644 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lovric, U. Erdbruegger, P. Kumpers, A. Woywodt, C. Koenecke, H. Wedemeyer, H. Haller, and M. Haubitz
Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
179 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al.
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Blood,
June 15, 2008;
111(12):
5530 - 5536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. James, P. D. Greenberg, M. C. Jensen, Y. Lin, J. Wang, B. G. Till, A. A. Raubitschek, S. J. Forman, and O. W. Press
Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane
J. Immunol.,
May 15, 2008;
180(10):
7028 - 7038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nomura, K. Ishii, Y. Kamitsuji, N. Uoshima, E. Ishikawa, H. Kitayama, and K. Hayashi
Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)-Treated Non-Hodgkin's Lymphoma
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2007;
13(2):
206 - 212.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. R. Jazirehi, M. I. Vega, and B. Bonavida
Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy
Cancer Res.,
February 1, 2007;
67(3):
1270 - 1281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
J. Immunol.,
July 1, 2006;
177(1):
362 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Perosa, E. Favoino, M. A. Caragnano, and F. Dammacco
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor
Blood,
February 1, 2006;
107(3):
1070 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E A Clark and J A Ledbetter
How does B cell depletion therapy work, and how can it be improved?
Ann Rheum Dis,
November 1, 2005;
64(suppl_4):
iv77 - iv80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Gillies, Y. Lan, S. Williams, F. Carr, S. Forman, A. Raubitschek, and K.-M. Lo
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
Blood,
May 15, 2005;
105(10):
3972 - 3978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Jazirehi, S. Huerta-Yepez, G. Cheng, and B. Bonavida
Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) Inhibits the Constitutive Nuclear Factor-{kappa}B Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug-induced Apoptosis
Cancer Res.,
January 1, 2005;
65(1):
264 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-L. Law, C. G. Cerveny, K. A. Gordon, K. Klussman, B. J. Mixan, D. F. Chace, D. L. Meyer, S. O. Doronina, C. B. Siegall, J. A. Francisco, et al.
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20-Auristatin Conjugates
Clin. Cancer Res.,
December 1, 2004;
10(23):
7842 - 7851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny
From the bench to the bedside: ways to improve rituximab efficacy
Blood,
November 1, 2004;
104(9):
2635 - 2642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Jazirehi, M. I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida
Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab
Cancer Res.,
October 1, 2004;
64(19):
7117 - 7126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results
Clin. Cancer Res.,
August 15, 2004;
10(16):
5327 - 5334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cragg, M. C. Bayne, T. M. Illidge, T. Valerius, P. W. N. Johnson, M. J. Glennie, I. Jilani, and M. Albitar
Apparent modulation of CD20 by rituximab: an alternative explanation
Blood,
May 15, 2004;
103(10):
3989 - 3991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boye, T. Elter, and A. Engert
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Ann. Onc.,
April 1, 2003;
14(4):
520 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Wiseman, E. Kornmehl, B. Leigh, W. D. Erwin, D. A. Podoloff, S. Spies, R. B. Sparks, M. G. Stabin, T. Witzig, and C. A. White
Radiation Dosimetry Results and Safety Correlations from 90Y-Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma: Combined Data from 4 Clinical Trials
J. Nucl. Med.,
March 1, 2003;
44(3):
465 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cragg, S. M. Morgan, H. T. C. Chan, B. P. Morgan, A. V. Filatov, P. W. M. Johnson, R. R. French, and M. J. Glennie
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Blood,
February 1, 2003;
101(3):
1045 - 1052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Kennedy, M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab
Blood,
February 1, 2003;
101(3):
1071 - 1079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. D. Davis, M. Jefford, P. Parente, and J. Cebon
Rational approaches to human cancer immunotherapy
J. Leukoc. Biol.,
January 1, 2003;
73(1):
3 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sapra and T. M. Allen
Internalizing Antibodies Are Necessary for Improved Therapeutic Efficacy of Antibody-targeted Liposomal Drugs
Cancer Res.,
December 15, 2002;
62(24):
7190 - 7194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al.
Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
May 15, 2002;
20(10):
2453 - 2463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K. Roberts, P. O. Livingston, D. B. Agus, J. Pinilla-Ibarz, A. Zelenetz, and D. A. Scheinberg
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice
Blood,
May 15, 2002;
99(10):
3748 - 3755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Carpenter, F. R. Appelbaum, L. Corey, H. J. Deeg, K. Doney, T. Gooley, J. Krueger, P. Martin, S. Pavlovic, J. Sanders, et al.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Blood,
April 15, 2002;
99(8):
2712 - 2719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Wu, G. J. Tan, M. A. Sherman, P. Clarke, T. Olafsen, S. J. Forman, and A. A. Raubitschek
Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange
Protein Eng. Des. Sel.,
December 1, 2001;
14(12):
1025 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, M. Corcoran, K. Subbiah, D. K. Hamlin, D. S. Wilbur, T. Johnson, L. Theodore, E. Yau, R. Mallett, D. L. Meyer, et al.
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
Blood,
October 15, 2001;
98(8):
2535 - 2543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Huhn, C. von Schilling, M. Wilhelm, A. D. Ho, M. Hallek, R. Kuse, W. Knauf, U. Riedel, A. Hinke, S. Srock, et al.
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Blood,
September 1, 2001;
98(5):
1326 - 1331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shan, A. K. Gopal, and O. W. Press
Synergistic Effects of the Fenretinide (4-HPR) and Anti-CD20 Monoclonal Antibodies on Apoptosis Induction of Malignant Human B Cells
Clin. Cancer Res.,
August 1, 2001;
7(8):
2490 - 2495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Colombat, G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran, V. Delwail, E. Deconinck, C. Haioun, C. Foussard, C. Sebban, et al.
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
Blood,
January 1, 2001;
97(1):
101 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, A. Rickers, K. Bommert, B. Dörken, and M. Y. Mapara
Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways
Cancer Res.,
December 1, 2000;
60(24):
7170 - 7176.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. A. Davis, A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment
J. Clin. Oncol.,
September 17, 2000;
18(17):
3135 - 3143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, et al.
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Blood,
August 15, 2000;
96(4):
1259 - 1266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press
Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line
Ann Intern Med,
June 6, 2000;
132(11):
916 - 918.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, R. L. Wahl, M. Saleh, A. Z. Rohatiner, S. J. Knox, J. A. Radford, A. D. Zelenetz, G. F. Tidmarsh, R. J. Stagg, and M. S. Kaminski
Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
J. Clin. Oncol.,
March 13, 2000;
18(6):
1316 - 1323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Illidge, M. S. Cragg, H. M. McBride, R. R. French, and M. J. Glennie
The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma
Blood,
July 1, 1999;
94(1):
233 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al.
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab
J. Clin. Oncol.,
June 1, 1999;
17(6):
1851 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shan, O. W. Press, T. T. Tsu, M. S. Hayden, and J. A. Ledbetter
Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths
J. Immunol.,
June 1, 1999;
162(11):
6589 - 6595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shan, J. A. Ledbetter, and O. W. Press
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Blood,
March 1, 1998;
91(5):
1644 - 1652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney, A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T.-M. Liles, B. K. Dallaire, et al.
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Blood,
September 15, 1997;
90(6):
2188 - 2195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. F. Eary, F. R. Appelbaum, P. J. Martin, C. C. Badger, W. B. Nelp, S. Glenn, G. Butchko, D. Fisher, B. Porter, et al.
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
N. Engl. J. Med.,
October 21, 1993;
329(17):
1219 - 1224.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. S. Kaminski, K. R. Zasadny, I. R. Francis, A. W. Milik, C. W. Ross, S. D. Moon, S. M. Crawford, J. M. Burgess, N. A. Petry, G. M. Butchko, et al.
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
N. Engl. J. Med.,
August 12, 1993;
329(7):
459 - 465.
[Abstract]
[Full Text]
|
|
|
|
|
